Q2 2025
Released Aug 5, 2025, before the open
10-Q filed Aug 5, 2025, 36 days after period end · 0001493152-25-011588
Q2 2025 · 10-Q
Revenue$622.85K$622.85K +595.4% vs Q2 2024+563.6% vs Q1 2025
Net Income-$2.21M-$2.21M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.41-$0.41 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$2,404,353N/M
Operating Cash Flowderived-$1,886,234N/M
Margins · derived
Operating margin-386.0%+3290.2 pt vs Q2 2024
Net margin-354.1%+3072.0 pt vs Q2 2024
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $622.85K | $89.57K | $0.00 | $500.00K |
| Net Income | -$2.21M | -$3.07M | -$3.55M | -$2.63M |
| EPS Diluted | -$0.41 | -$0.56 | -$0.68 | -$0.61 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR